



www.G2Gconsulting.com
www.michbio.org

Bioscience Grant Report – June 2014

	Title (Agency)	Opp. Number	Description	Deadline (pre-proposal)	Funding Level	Eligibility	Link
			NEURAL SYSTEMS				
1	DoD Neurofibromatosis Investigator-Initiated Research Award	W81XWH-14-NFRP-IIRA	The NFRP Investigator-Initiated Research Award supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care. Research projects may focus on any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial.	5/27/14	\$6,004,000 \$900,000 for a four year project.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=256021
2	DoD Neurofibromatosis Exploration-Hypothesis Development Award	W81XWH-14-NFRP-EHDA	The Exploration - Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.	7/24/14	\$1,280,000	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=256030

3	DoD Neurofibromatosis Clinical Trial Award	W81XWH-14-NFRP-CTA	The Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.	7/24/14	\$2,880,000	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=256029
4	Lab to Marketplace: Tools for Brain and Behavioral Research (R43/R44)	PA-14-250	The NIH and other research sponsors invest a significant amount of funds in the development of new technologies to study the brain and behavior, from basic and clinical perspectives, through a variety of mechanisms, including, from NIH, the R01, R21, R33, P01, P41, and P50 grants. This investment has produced a large number of technologies that include hardware (e.g., instruments, devices, etc.), software (e.g., computational models, informatics tools, data analytic methods, etc.) and wetware (e.g., cell-free assays, bioactive agents, imaging probes, etc.). While these technologies are put to good use by their developers, such non-commercial developers devote little attention to making their tools robust and easy to use by the broad research community. Consequently, the promise of these advanced technologies is often realized only by the tools' developers and their close associates.	5/7/17	\$150,000 for Phase I awards and \$1,000,000 for Phase II awards -	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-14-250.html
			THERAPY				
5	DoD Peer Reviewed Medical Technology/Therapeutic Development Award	W81XWH-14-PRMRP-TTDA	This award is a product-driven award intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, patient care, and/or quality of life, in at least one of the Congressionally directed Topic Areas. Products in development should be responsive to the health care needs of military service members, Veterans, and/or beneficiaries. The product(s) to be developed may be pharmacologic agents (drugs or biologics), devices, and/or clinical guidance for standard of care.	10/17/14	\$13,500,000 1.5 M per three year project.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254517

6	Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01)	PAR-14-225	This announcement aims to fund applications designed to assess the clinical value of adjuncts prescribed to chronic pain patients together with opioid analgesics. Adjuncts of interest are either approved by the FDA or have previously been studied as an Investigational New Drug. Studies with adjuncts of interest should be focused on enhancing analgesia, rather than on reducing an adverse effect.	9/7/17	\$2,960,000	Small businesses; For profit organization other than small businesses	http://www.grants.gov/web/grants/view-opportunity.html?oppId=255315
7	Limited Competition for NIH-Industry Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3) And Discovering Pediatric New Therapeutic Uses for Existing Molecules (UH2/UH3)	PAR-14-210 PAR-14-212	The UH2/UH3 is a two stage application. 1. The UH2 (Stage 1) may be used to support milestone-driven preclinical studies to verify target engagement in a disease model and/or Phase 1b clinical trials using the selected Agent in its existing formulation/route of administration to identify the dose or exposure of the Agent in the proposed patient group, and inform patient selection. Support for the UH2 may be requested for a period that may vary from six months up to one year. UH2 projects that have met the scientific milestones and feasibility requirements will be eligible for rapid transition to the second UH3 stage after NIH administrative review. 2. The UH3 (Stage 2) will support milestone-driven Phase 2a trials to demonstrate that the Agent, made available for this program by the pharmaceutical partners, modulates the target and has the potential to yield the desired clinical outcome in the proposed disease population. The project period for the UH3 stage is up to two years.	1/16/15	Over \$500,000, project determinant	Small Businesses	http://www.grants.gov/web/grants/view-opportunity.html?oppId=255054
			CANCER				
8	DoD Prostate Cancer Synergistic Idea Development Award	W81XWH-14-PCRP-PCBRSA	The Synergistic Idea Development Award supports new ideas that represent innovative approaches to prostate cancer research involving two or three independent, faculty-level (or equivalent) Principal Investigators (PIs). These investigators should utilize their complementary and synergistic perspectives to address a central problem or question in prostate cancer research. The Synergistic Idea Development Award requires that multiple investigators jointly design a single project, with comparable levels of intellectual input from each PI. The research project must be supported by the unique expertise, experience, and abilities of each PI, and it must clearly define the synergistic components that will facilitate and accelerate progress in a way that could not be accomplished through independent efforts.	9/24/14	\$10,800,000 \$750,000 for a three year project.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254792

9	DoD Lung Cancer Concept Award	W81XWH-14- LCRP-CA	The Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer or create an entirely new avenue for investigation. Submissions from and partnerships with investigators at Military Treatment Facilities (MTFs), military labs, the Department of Veterans Affairs (VA) Medical Centers and research laboratories are strongly encouraged. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. Presentation of preliminary data is not consistent with the intent of the Concept Award mechanism and is discouraged.	9/11/14	\$1,920,000	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=255571
10	DoD Prostate Cancer Biomarker Development Award	W81XWH-14- PCRP-BDA	The PCRP Biomarker Development Award was introduced in FY12 to fund near-term validation or qualification studies that will advance known prostate cancer biomarkers into the clinical setting. Specifically, this award will support high-impact research aimed at multi-institutional validation and/or qualification of prostate cancer biomarkers for crucial decision making in prostate cancer management, including detection of aggressive disease, prognosis and progression, and prediction and assessment of response to therapy.	9/24/14	\$3,600,000 Three year project.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254789
11	DoD Prostate Cancer Laboratory-Clinical Transition Award	W81XWH-14- PCRP-LCTA	The Laboratory - Clinical Transition Award supports product-driven preclinical studies of promising lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. Lead Agents: It is anticipated that lead agent development projects supported by this award will focus on generating pharmacology and toxicology data in preclinical studies for inclusion in a FDA Investigational New Drug (IND) application and/or establishing agent production according to current Good Manufacturing Practice (cGMP).	9/24/14	\$4,800,000 1.5M per three year project.	Unrestricted	http://cdmrm.army.mil/funding/pa/13pcrplcta_pa.pdf

12	DoD Prostate Cancer Clinical Exploration Award	W81XWH-14-PCR-CEA	The Exploration – Hypothesis Development Award supports the exploration of highly innovative, untested, potentially high-gain concepts, theories, paradigms, and/or methods that address an important problem in prostate cancer. Results of studies conducted through this award may provide the scientific rationale upon which a new hypothesis can be based or initial proof-of-principle of an innovative hypothesis. The PCR-CEA seeks applications from investigators from a wide spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research. In addition, applicants are expected to address at least one of the PCR-CEA focus areas and one of the PCR-CEA overarching challenges.	10/29/14	\$2,200,000	Unrestricted	http://cdmrap.rmy.mil/funding/pa/14pcrcea_pa.pdf
13	Molecular and Cellular Characterization of Screen-Detected Lesions (U01)	RFA-CA-14-010	The goal of this Funding Opportunity Announcement (FOA), is to solicit applications from independent, multi-disciplinary teams to undertake a comprehensive molecular and cellular characterization of tumor tissue, cell, and microenvironment components to distinguish screen-detected early lesions from interval and symptom-detected cancers. Individual research teams will pursue one or more aspects of molecular and cellular analysis of one or more of the specified tumor sites (breast, prostate, lung, melanoma, and pancreas). Use of enabling approaches and technologies will be encouraged to determine both the cellular and molecular phenotypes of early lesions, to assess the degree to which the behavior of these lesions is predictable or stochastic, and to allow better predictions of the fate of early lesions. To achieve the goal of a comprehensive characterization of screen-detected lesions, each research team should include cancer researchers and clinicians with multi-disciplinary expertise. The individual research teams funded through this FOA are expected to participate in a collaborative Consortium.	9/17/14	\$500,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-14-010.html
REGENERATIVE MEDICINE							

14	DoD Duchenne Muscular Dystrophy Investigator-Initiated Research Award And Therapeutic Idea Award	W81XWH-14-DMDRP-IIRA W81XWH-14-DMDRP-TIA	<p>The DMDRP Investigator-Initiated Research Award (IIRA) supports translational research that will accelerate the movement of promising ideas in DMD into clinical applications. While the ultimate goal of translational research is to move an observation forward into clinical application, translational research is most effective as a two-way continuum between the bench and the bedside.</p> <p>The DMDRP Therapeutic Idea Award mechanism is designed to promote new ideas that are still in the early stages of development with the potential to yield high-impact data and new avenues of investigation for novel therapeutics for DMD treatment. This award mechanism supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in DMD therapeutics.</p>	10/22/14	\$2,016,000 (Only one grant) \$480,000	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=255969 http://www.grants.gov/web/grants/view-opportunity.html?oppId=255972
			GENERAL				
15	DoD Peer Reviewed Medical Clinical Trial Award; USAMRAA	W81XWH-14-PRMRP-CTA	<p>The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Congressionally directed FY14 PRMRP Topic Areas. See Program Announcement for Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials to demonstrate feasibility or inform the design of more advanced trials (e.g., pilot, first in human, Phase 0), through large-scale trials to determine efficacy in relevant patient populations. All studies must be responsive to the health care needs of the military service members, Veterans, and/or beneficiaries; however, the use of military or Veteran populations is not required.</p>	10/17/14	\$36 M total 6 trials will be funded.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254514

16	Novel Technologies for Rapid and Sensitive Biomonitoring in Humans (R43/R44) SBIR	RFA-ES-14-005	This grant funds the development of point-of-care or bench top instruments, or other laboratory-based approaches for the characterization of major classes of analyses that include known and suspected toxicants and their major metabolites in human biological samples, including blood, urine, and saliva, which are likely to be available from both prospective and retrospective epidemiological cohorts. The focus of technology development is on the ability to detect multiple chemical analyses with high sensitivity and specificity in low volumes of biological specimens.	8/15/14	\$3,000,000 4-8 Phase II renewals and new Phase I awards.	Small Businesses	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254910
17	Diabetes Impact Award-Closed Loop Technologies: Development and Integration of Novel Components for an Automated Artificial Pancreas System (DP3)	RFA-DK-14-015	This grant encourages applications from institutions/organizations proposing original research addressing the development of new technologies that may be integrated in a wearable, portable, automated, closed loop system for a physiological glucose control in individuals with Type 1 Diabetes.	11/24/14	\$6,000,000 2-5 awards.	Small Businesses	http://www.grants.gov/web/grants/view-opportunity.html?oppId=255220
18	DoD Peer Reviewed Orthopedic Clinical Trial Development Award	W81XWH-14-PRORP-CTDA	The PRORP CTDA is intended to support the planning and development activities necessary to support preparation for clinical trials with the potential to have a significant impact on Warfighters and Veterans recovering from traumatic orthopedic injuries. The clinical trials proposed may be focused on any aspect of treatment of orthopedic injuries that addresses at least one of the FY14 PRORP CTDA Focus Areas, including the evaluation of promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. All applications are required to justify the relevance of the proposed project to military and/or Veteran populations affected by combat-related orthopedic injury.	10/24/14	\$1,200,000 Expects to fund 4 awards.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254520

19	DoD Peer Reviewed Orthopedic Translational Research Award	W81XWH-14-PRORP-TRA	The PRORP Translational Research Award is designed to support multidisciplinary translational research that will accelerate the movement of promising ideas in orthopedic research into clinical applications to benefit Warfighters and Veterans recovering from traumatic orthopedic injuries. To encourage meaningful and productive multidisciplinary collaborations, there must be at least one laboratory scientist and at least one clinician participating in the research.	10/24/14	\$2,250,000 Two awards will be funded.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254522
20	DoD Peer Reviewed Orthopedic Idea Development Award	W81XWH-14-PRORP-IDA	The PRORP Idea Development Award is designed to promote new ideas that are still in the early stages of development and have the potential to yield highly impactful data and new avenues of investigation. This mechanism supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in the clinical care of combat-related orthopedic injuries.	10/24/14	\$3,000,000 Four awards will be funded.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=254521
21	DoD Tuberous Sclerosis Complex Pilot Clinical Trial Award	W81XWH-14-TSCR-PCTA	The TSCR Pilot Clinical Trial Award mechanism supports exploratory studies involving limited human exposure that produce diagnostic or therapeutic information (e.g., screening studies, microdose studies), toxicity studies of an intervention, and studies to determine the mechanism of action and side effects of an intervention. These studies should be aimed at obtaining preliminary data leading to the development of interventions, as well as clinical biomarkers, and endpoints, with the potential to improve TSC outcomes.	7/24/14	Three different amounts: \$640,000;	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=256020

22	DoD Tuberos Sclerosis Complex Exploration-Hypothesis Development Award	W81XWH-14-TSCRPEHDA	The TSCRPE Exploration – Hypothesis Development Award mechanism was first offered in FY07. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design. The presentation of preliminary and/or published data is encouraged, but not required. The proposed research project should be innovative.	7/24/14	\$1,120,000; 7 expected awards.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=256018
23	DoD Tuberos Sclerosis Complex Idea Development Award	W81XWH-14-TSCRPEIDA	The FY14 TSCRPE Idea Development Award promotes new ideas that are in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation. This award mechanism supports conceptually innovative, high-risk/potentially high-reward research that could ultimately lead to critical discoveries in TSC research and/or improvements in patient care. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.	7/24/14	\$2,960,000 \$425,000 per award.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=256019
24	Translational Programs in Lung Diseases (P01)	PAR-14-245	This FOA invites submission of Program Project (P01) applications from institutions/organizations that will perform collaborative, translational research with the goal of using mechanistic research as the basis for the rational design of clinical applications to improve prevention, diagnosis and/or treatment of lung diseases and sleep disorders.	5/19/14	\$1,750,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-245.html
25	Research on Chronic Overlapping Pain Conditions (R21)	PA-14-243	The purpose of this FOA is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions.	9/7/17	\$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-243.html

26	DoD Spinal Cord Injury Clinical Trial Award Qualitative Research Award And Investigator-Initiated Research Award	W81XWH-14-SCIRP-CTA	The SCIRP Clinical Trial Award mechanism was first offered in FY12. Since then, 30 Clinical Trial Award applications have been received, and 7 have been recommended for funding. The SCIRP Clinical Trial Award supports human subjects research with the potential to have a major impact on the treatment or management of SCI and its consequences in military Service Members, Veterans, or other individuals. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction.	10/30/14	\$9,600,000 Four total awards	Unrestricted	http://cdmrp.army.mil/funding/pa/14scirpira_p.pdf
----	---	---------------------	--	----------	----------------------------------	--------------	---